Journal of Skin Cancer最新文献

{"title":"Diagnosis and Management of Lentigo Maligna: Clinical Presentation and Comprehensive Review.","authors":"Piyu Parth Naik","doi":"10.1155/2021/7178305","DOIUrl":"10.1155/2021/7178305","url":null,"abstract":"<p><p>Lentigo maligna (LM), also known as Hutchinson's melanotic freckle, is a form of in situ melanoma characterized by the proliferation of atypical melanocytes along the basal epidermis in sun-damaged skin. If left untreated, LM will progress to lentigo maligna melanoma (LMM), a form of invasive melanoma with the same prognosis as other forms of invasive melanoma. LM is more common in the elderly, with a peak occurrence between the ages of 65 and 80 years. LM, however, is rarely present on the trunk and extremities. The diagnosis of LM, confirmed by histopathological and biopsy examination, is based on clinical and dermoscopic features. It typically begins as a tan-brown macule or patch, but it can progress to a variegated pigmentation with dark black color or even amelanotic characteristics. The risk factors involved in the LM development include a history of sunburns, lighter skin types, advanced age, history of nonmelanoma skin cancers, and tendency to form solar lentigines. This article explains the clinical presentation of LM, also reviews the available information on the diagnosis and management of LM, and discusses the potential of such information in facilitating the future prospective.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"7178305"},"PeriodicalIF":1.1,"publicationDate":"2021-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39276708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy.","authors":"Manish D Angrish,&nbsp;Arun Agha,&nbsp;Rossanna C Pezo","doi":"10.1155/2021/9120162","DOIUrl":"https://doi.org/10.1155/2021/9120162","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved survival in many advanced cancers including advanced melanoma, renal cell, urothelial, and non-small-cell lung cancers. However, not all patients respond, and immune-related adverse events (irAEs) are common. Commensal gut bacteria may serve as an immunoregulatory link-mediating ICI response and toxicity. Recent studies have shown that a lack of bacterial diversity, known as gut dysbiosis, can have an adverse impact on patients' response to ICIs and predispose to the development of irAEs. Data were collected from 167 patients with metastatic melanoma who received antibiotics within 30 days prior to and/or after initiation of ICI and patients who received NSAIDs, statins, steroids, or proton-pump inhibitors (PPI) within 30 days prior to ICI initiation. The primary outcome was time-to-discontinuation (TTD) of ICI therapy, measured from the date of ICI initiation to the last treatment date. The secondary outcome of interest was toxicity, with incidence of irAEs graded as per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Here, we demonstrate that individuals who received antibiotics had a significantly shorter time-to-discontinuation (TTD) of the ICI therapy as opposed those who were not administered antibiotics. Consistent with results from previous research, we propose that antibiotics have a negative effect on a patient's response to ICI therapy, most likely due to the result of gut dysbiosis, and should be critically assessed in terms of their use in patients undergoing ICI treatment.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"9120162"},"PeriodicalIF":1.1,"publicationDate":"2021-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39273455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Sailors' Protective Behaviors in Fishing Spots against the Risks of Sunlight and Skin Cancer: A Qualitative Study in Iran.","authors":"Ali Asadian,&nbsp;Mojtaba Fattahi Ardakani,&nbsp;Ahmad Sotoudeh,&nbsp;Moradali Zareipour,&nbsp;Ehsan Movahed","doi":"10.1155/2021/9954946","DOIUrl":"https://doi.org/10.1155/2021/9954946","url":null,"abstract":"<p><strong>Introduction: </strong>The growing rate of nonmelanoma skin cancer (NMSC) and melanoma has been a great challenge for global health system. The present research aims to determine sailors' protective behaviors against the risks of sunlight and skin cancer in Iran.</p><p><strong>Materials and methods: </strong>The present research was qualitative in type, and its data were collected from August to December 2019. To this aim, 23 participants were recruited with whom semistructured interviews were held. The data collection continued until data saturation, and the interviews were coded in MAXQDA 10. Conventional content analysis was used to analyze the qualitative data.</p><p><strong>Results: </strong>Analysis of sailors' perceptions and experiences revealed 7 categories: protective behaviors, hard personal and familial conditions, social interactions, poor social support, feeling of satisfaction, self-care, and fear.</p><p><strong>Conclusion: </strong>Sailors are prone to skin cancer due to their specific work conditions. Perceptions and determinants of skin cancer and protective behaviors against sunlight were identified among sailors. Promotion of protective behaviors and beliefs that impeded preventive behaviors are among issues that require special attention.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"9954946"},"PeriodicalIF":1.1,"publicationDate":"2021-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39258624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma.","authors":"A A Formozo,&nbsp;J R Gomes,&nbsp;R A Schmerling,&nbsp;A C Buzaid","doi":"10.1155/2021/5531864","DOIUrl":"https://doi.org/10.1155/2021/5531864","url":null,"abstract":"<p><strong>Background: </strong>Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it has been used more frequently in combination with anti-PD-1. Since the development of anti-PD1 for melanoma, rechallenge with ipilimumab has not been considered, although its use was considered in early trials.</p><p><strong>Cases: </strong>In this study, we analyzed 22 patients with metastatic melanoma who had benefited from the first treatment with ipilimumab, but eventually had progressive disease. They received ipilimumab at the same dose as the first treatment. Most of the patients received the second course after six months or more from the first treatment with ipilimumab. The median progression-free survival (mPFS) of the treatment with ipilimumab was 8.9 months, and the median progression-free survival of the second course was 6.3 months.</p><p><strong>Conclusion: </strong>There are limited data on rechallenge with ipilimumab addressing progression-free survival (PFS). In our analysis, twenty-two patients treated with a second course of ipilimumab were analyzed and most of them had a significant benefit. Despite the current alternatives for salvage therapies, rechallenging with ipilimumab might be an alternative to be considered in patients who had initial benefit.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"5531864"},"PeriodicalIF":1.1,"publicationDate":"2021-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39203009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D and Vitamin D Analogs as Adjuncts to Field Therapy Treatments for Actinic Keratoses: Current Research and Future Approaches.","authors":"Zafer Sattouf,&nbsp;Steven J Repas,&nbsp;Jeffrey B Travers,&nbsp;Craig A Rohan","doi":"10.1155/2021/9920558","DOIUrl":"https://doi.org/10.1155/2021/9920558","url":null,"abstract":"<p><p>Actinic keratoses (AK), also known as solar keratoses, are precancerous hyperkeratotic papules caused by long-term exposure to ultraviolet radiation. Management of AK prior to progression to cutaneous malignancy represents an important window of intervention. This is important on a population level, given the high incidence, morbidity, financial costs, and the low but measurable risk of mortality from cutaneous neoplasia. Treatments for AK have been refined for many years with significant progress over the past decade. Those recent advancements lead to questions about current treatment paradigms and the role of harnessing the immune system in field therapies. Recent studies suggest a key interplay between vitamin D and cancer immunity; in particular, the systemic and/or topical vitamin D analogs can augment field therapies used for severe actinic damage. In this review, we will examine the literature supporting the use of vitamin D-directed therapies to improve field therapy approaches. An enhanced understanding of these recent concepts with a focus on mechanisms is important in the optimized management of AK. These mechanisms will be critical in guiding whether selected populations, including those with immunosuppression, heritable cancer syndromes, and other risk factors for skin cancer, can benefit from these new concepts with vitamin D analogs and whether the approaches will be as effective in these populations as in immunocompetent patients.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"9920558"},"PeriodicalIF":1.1,"publicationDate":"2021-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39220539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Effect of Alpha and Hydrocortisone Ointments on Prevention of Acute Skin Complications Due to Radiotherapy in Breast Cancer Patients.","authors":"Mansour Rezaei,&nbsp;Ahmad Khoshay,&nbsp;Nasrin Amirifard,&nbsp;Ali Goli,&nbsp;Alireza Abdi","doi":"10.1155/2021/5575688","DOIUrl":"https://doi.org/10.1155/2021/5575688","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy in breast cancer patients is associated with acute and delayed side effects. This study aimed to compare the effect of alpha and hydrocortisone 1% (H1%) ointments on prevention of acute skin complications due to radiotherapy in breast cancer patients.</p><p><strong>Methods: </strong>This clinical trial was conducted on 86 patients with breast cancer in the radiotherapy center of Imam Reza Hospital of Kermanshah, Iran. Using the records, the patients were selected and randomly divided into alpha and H1% groups after obtaining informed consent. The severity of dermatitis, complications, and patient complaints during treatment were evaluated weekly for up to 6 weeks by RTOG criteria. Data were analyzed using SPSS-16 software.</p><p><strong>Results: </strong>At the end of the third, fourth, fifth, and sixth weeks, 10 (11.7%), 25 (29.1%), 53 (61.6%), and 28 (32.6%) patients had skin complications, respectively. In weeks 5 and 6 in the H1 group, the incidence of complications was higher (<i>P</i> = 0.001). The frequency of pain and burning complaints at the end of the third, fourth, fifth, and sixth weeks was 15 (17.4%), 37 (43.0%), 52 (60.5%), and 1(1.2%), respectively. Pain and burning intensity in the fourth and fifth weeks in the H1 group was lower than alpha (<i>P</i> = 0010). Complaints of skin itching at the end of the third, fourth, and fifth weeks were 16 (18.6%), 25 (29.1%), and 28 (32.6), respectively. This complication was lower in the H1% group during these weeks (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Alpha ointment is more effective than H1% in relieving pain and burning, preventing complications except itching. It seems using an alpha ointment or combining it with H1% is an appropriate strategy to reduce the rate of injuries and skin complications of radiotherapy.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"5575688"},"PeriodicalIF":1.1,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39081948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Keratinocyte Skin Cancers in General Surgery: The Impact of Anaesthesia, Trainee Supervision, and Choice of Reconstruction.","authors":"William McSweeney,&nbsp;Matthew Leaning,&nbsp;Darius Dastouri","doi":"10.1155/2021/5537273","DOIUrl":"https://doi.org/10.1155/2021/5537273","url":null,"abstract":"<p><strong>Background: </strong>Keratinocyte skin cancers are common in Australia, incurring disproportionately high health expenditure in comparison with mortality. General surgeons often excise these lesions as day-surgery. Balancing individual complexities of these cancers with trainee supervision and health expenditure is key to deliver efficacious care and maintain day-surgery volume for patients during a pandemic.</p><p><strong>Methods: </strong>A retrospective, cross-sectional study was performed, examining 414 procedures from January 2019 to December 2020. Pathology was reviewed, and benign lesions excluded. Complete excision was based on 5 mm margins for squamous cell carcinoma (SCC), 0.5 mm microscopic margins for low-risk basal cell carcinoma (BCC) subtypes, and 3 mm for high-risk. Results of trainee-performed local anesthetic (LA) excision and general anesthetic (GA) excision (consultant scrubbed) were compared.</p><p><strong>Results: </strong>288 excisions were reviewed for completeness, location, and reconstruction modality. 69% were BCC (199), and 31% were SCC (89). These were excised under GA (72.5%) and LA (27.5%). 25.6% of BCC excisions were \"close,\" and 22.6% were \"positive\" under GA, whilst 31% were \"close\" and 15.5% were \"positive\" under LA. 52.8% of SCC excisions were \"close,\" and 7.8% were \"positive\" under GA, compared with 42.8% \"close\" and 9.5% \"positive\" under LA. Complex reconstruction (skin graft, flap) was more common under GA (38% SCC and 36.1% BCC), but occurred at a modest rate under LA (22% BCC and 28.5% SCC).</p><p><strong>Conclusions: </strong>The results confirm that comparable margins and reconstruction options are achievable when excising keratinocyte cancers under LA by surgical trainees. This is fundamental in cost and timesaving, as well as reducing risk of aerosolisation of virus during GA, in a pandemic.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"5537273"},"PeriodicalIF":1.1,"publicationDate":"2021-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38954424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Sun Protection Interventions Delivered to Adolescents in a Secondary School Setting: A Systematic Review.","authors":"Bronwen M McNoe,&nbsp;Kate C Morgaine,&nbsp;Anthony I Reeder","doi":"10.1155/2021/6625761","DOIUrl":"https://doi.org/10.1155/2021/6625761","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this systematic review is to summarise the evidence of the effectiveness of interventions targeted to adolescents (13 to 18 years inclusive) and delivered in a secondary school setting with the purpose of improving sun protection behaviour, reducing ultraviolet radiation (UVR) exposure, and/or improving physiological outcomes related to UVR exposure (such as erythema or naevi development).</p><p><strong>Methods: </strong>Peer-reviewed journal articles were identified from seven database searches (Cochrane, Embase, CINAHL, Scopus, Medline, PsycInfo, and Web of Science) to January 2020, forward citation searches of relevant articles, and monitoring of WHO INTERSUN UVR list server for recent publications. Relevant articles were collected and critically analysed using the Effective Public Health Practice framework. Two reviewers independently reviewed, and when deemed eligible, extracted data and performed quality appraisals for each study.</p><p><strong>Results: </strong>Thirteen studies met the criteria for inclusion in the review. There were no studies that met a \"strong\" quality rating, five received a \"moderate\" quality rating, and eight studies a \"weak\" quality rating. Three of those with a moderate rating found evidence for effectiveness. The most promising interventions overall (including the pilot/uncontrolled studies) were those that moved beyond a pure health education approach and used innovative approaches such as the provision of shade, or use of technology (e.g., appearance-based apps or real-time ultraviolet index (UVI) monitors).</p><p><strong>Conclusions: </strong>There is a lack of high-quality published studies investigating the interventions delivered in a secondary school setting to protect students from UVR. The evidence could be strengthened if researchers used consistent, standardised outcome measures for sun protection exposure and behaviour. Other factors limiting the strength of evidence were short follow-up times (largely less than 6 months) and/or nonrobust study design.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2021 ","pages":"6625761"},"PeriodicalIF":1.1,"publicationDate":"2021-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25501175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inguinal Lymph Node Dissection for Advanced Stages of Plantar Melanoma in a Low-Income Country.","authors":"Ollo Roland Somé,&nbsp;Malick Diallo,&nbsp;Damien Konkobo,&nbsp;Nassirou Yabré,&nbsp;Valentin Konségré,&nbsp;Issouf Konaté,&nbsp;Sidy Ka","doi":"10.1155/2020/8854460","DOIUrl":"https://doi.org/10.1155/2020/8854460","url":null,"abstract":"<p><strong>Background: </strong>Advanced stages of plantar acral lentiginous melanoma are common in Africa. Inguinal lymph node dissection (ILND) in these cases plays a critical role in disease-free and overall survival. Our study aims to share our experience in ILND for advanced plantar melanomas. <i>Methods and Study Design</i>. Four-year prospective study. <i>Patients</i>. We included all documented cases of advanced stage plantar melanoma with clinically detectable inguinal lymph node metastasis. Twenty-two of 27 patients identified-with mean age 56 years-underwent ILND. <i>Studied Variables.</i> Tumor patterns and stage, surgery, morbidity, oncologic pathology, and evolution were studied. Statistical software assessed the overall survival (OS).</p><p><strong>Results: </strong>Plantar lesions were all excised with a cancer-free margin (3 cm). ILND was performed for 22 patients with visible (<i>n</i> = 11), palpable (<i>n</i> = 7), and ulcerous (<i>n</i> = 4) lymphadenopathies. It was performed through an S-shaped (<i>n</i> = 11) or ellipse-shaped skin incision (<i>n</i> = 11). The tumors were AJCC stage III (<i>n</i> = 18) and IV (<i>n</i> = 2). We found high Breslow index tumor thickness (>3 mm) and an advanced Clark IV stage (<i>n</i> = 20). All operative wounds healed within 46 days (21-90). Wound healing was delayed by suture failure (<i>n</i> = 16), lymphorrhoea (<i>n</i> = 22), and infection (<i>n</i> = 18). After 29 months, three patients had complete remissions, seven had recurrences, and twelve patients had died. The overall survival (OS) at one year was 56%. In two patients with AJCC stage III disease, the OS was better (22 months).</p><p><strong>Conclusion: </strong>In low-income countries, ILND in advanced stages of plantar foot melanoma is a valuable surgical treatment option. Alongside ILND adjuvants, treatment must be available and accessible to improve survival.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2020 ","pages":"8854460"},"PeriodicalIF":1.1,"publicationDate":"2020-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8854460","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Treatment for Melanoma Brain Metastases.","authors":"Mantas Janavicius,&nbsp;Nadezda Lachej,&nbsp;Giedre Anglickiene,&nbsp;Ieva Vincerzevskiene,&nbsp;Birute Brasiuniene","doi":"10.1155/2020/7520924","DOIUrl":"https://doi.org/10.1155/2020/7520924","url":null,"abstract":"<p><strong>Background: </strong>Historically, melanoma with brain metastases has a poor prognosis. In this retrospective medical record review, we report basic clinicopathological parameters and the outcomes of patients with melanoma and brain metastases treated with different treatment modalities before the era of immunotherapy and modern radiotherapy technique.</p><p><strong>Methods: </strong>Patients with metastatic melanoma were treated with surgery, radiotherapy, and/or systemic therapy from 1998 to 2017. In our study, they were identified and stratified depending on treatment methods. Overall survival was defined as the time from the date of brain metastases to the death or last follow-up (2019 June 1^st). Survival curves were estimated using the Kaplan-Meier method that was employed to calculate the hazard ratio.</p><p><strong>Results: </strong>Six (12%) of 50 patients are still alive as of the last follow-up. The median overall survival from the onset of brain metastases was 11 months. The longest survival time was observed in patients treated by surgery followed by radiotherapy, surgery followed by radiotherapy and systemic therapy, and also radiotherapy followed by systemic therapy. The shortest survival was observed in the best supportive care group and patients treated by systemic therapy only.</p><p><strong>Conclusions: </strong>Patients with brain metastases achieved better overall survival when treated by combined treatment modalities: surgery followed by radiotherapy (26.6 months overall survival), combining surgery, radiotherapy, and systemic therapy (18.7 months overall survival), and also radiotherapy followed by systemic therapy (13.8 months overall survival).</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2020 ","pages":"7520924"},"PeriodicalIF":1.1,"publicationDate":"2020-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7520924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38341019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}